| First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial GJ Morgan, FE Davies, WM Gregory, K Cocks, SE Bell, AJ Szubert, ... The Lancet 376 (9757), 1989-1999, 2010 | 633 | 2010 |
| Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life … K Cocks, MT King, G Velikova, M Martyn St-James, PM Fayers, JM Brown Journal of Clinical Oncology 29 (1), 89-96, 2011 | 628 | 2011 |
| Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 K Cocks, MT King, G Velikova, G de Castro Jr, MM St-James, PM Fayers, ... European journal of cancer 48 (11), 1713-1721, 2012 | 473 | 2012 |
| Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related … KJ Harrington, RL Ferris, G Blumenschein, AD Colevas, J Fayette, ... The Lancet Oncology 18 (8), 1104-1115, 2017 | 422 | 2017 |
| Sample size calculations for pilot randomized trials: a confidence interval approach K Cocks, DJ Torgerson Journal of clinical epidemiology 66 (2), 197-201, 2013 | 417 | 2013 |
| International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium C Coens, M Pe, AC Dueck, J Sloan, E Basch, M Calvert, A Campbell, ... The Lancet Oncology 21 (2), e83-e96, 2020 | 260 | 2020 |
| An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with … K Cocks, D Cohen, F Wisløff, O Sezer, S Lee, E Hippe, P Gimsing, ... European Journal of Cancer 43 (11), 1670-1678, 2007 | 253 | 2007 |
| Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, ... The Lancet Oncology 17 (11), e510-e514, 2016 | 211 | 2016 |
| Patients report improvements in continuity of care when quality of life assessments are used routinely in oncology practice: secondary outcomes of a randomised controlled trial G Velikova, A Keding, C Harley, K Cocks, L Booth, AB Smith, P Wright, ... European journal of cancer 46 (13), 2381-2388, 2010 | 205 | 2010 |
| Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials K Cocks, MT King, G Velikova, PM Fayers, JM Brown European Journal of Cancer 44 (13), 1793-1798, 2008 | 191 | 2008 |
| Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised … GJ Morgan, JA Child, WM Gregory, AJ Szubert, K Cocks, SE Bell, ... The lancet oncology 12 (8), 743-752, 2011 | 189 | 2011 |
| Can patient involvement improve patient safety? A cluster randomised control trial of the Patient Reporting and Action for a Safe Environment (PRASE) intervention R Lawton, JK O'Hara, L Sheard, G Armitage, K Cocks, H Buckley, ... BMJ Quality & Safety 26 (8), 622-631, 2017 | 150 | 2017 |
| Health-related quality-of-life results from the open-label, randomized, phase III ASPIRE trial evaluating carfilzomib, lenalidomide, and dexamethasone versus lenalidomide and … AK Stewart, MA Dimopoulos, T Masszi, I Špička, A Oriol, R Hájek, ... Journal of Clinical Oncology 34 (32), 3921-3930, 2016 | 105 | 2016 |
| Can staff and patient perspectives on hospital safety predict harm-free care? An analysis of staff and patient survey data and routinely collected outcomes R Lawton, JK O'Hara, L Sheard, C Reynolds, K Cocks, G Armitage, ... BMJ Quality & Safety 24 (6), 369-376, 2015 | 96 | 2015 |
| Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping DC Johnson, S Corthals, C Ramos, A Hoering, K Cocks, NJ Dickens, ... Blood, The Journal of the American Society of Hematology 112 (13), 4924-4934, 2008 | 92 | 2008 |
| Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review M Pe, L Dorme, C Coens, E Basch, M Calvert, A Campbell, C Cleeland, ... The Lancet Oncology 19 (9), e459-e469, 2018 | 86 | 2018 |
| International development of an EORTC questionnaire for assessing health-related quality of life in chronic myeloid leukemia patients: the EORTC QLQ-CML24 F Efficace, M Baccarani, M Breccia, S Saussele, G Abel, G Caocci, ... Quality of life research 23, 825-836, 2014 | 82 | 2014 |
| Minimally important differences for interpreting EORTC QLQ-C30 scores in patients with advanced breast cancer JZ Musoro, C Coens, F Fiteni, P Katarzyna, F Cardoso, NS Russell, ... JNCI cancer spectrum 3 (3), pkz037, 2019 | 72 | 2019 |
| Thalidomide Combinations Improve Response Rates; Results from the MRC IX Study. GJ Morgan, FE Davies, RG Owen, AC Rawstron, S Bell, K Cocks, ... Blood, The Journal of the American Society of Hematology 110 (11), 3593-3593, 2007 | 69 | 2007 |
| Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and … F Efficace, M Breccia, S Saussele, U Kossak-Roth, A Cardoni, G Caocci, ... Annals of hematology 91, 1371-1381, 2012 | 67 | 2012 |
